China Largest Factory Manufacturer Supply Beta-Nicotinamide Mononucleotide(NMN) Cas 1094-61-7 For stock delivery

China Largest Factory Manufacturer Supply Beta-Nicotinamide Mononucleotide(NMN) Cas 1094-61-7 For stock deliveryβ-Nicotinamide mononucleotide (NMN) is a natural product which exists in small quantity in most plants, such as edamame, broccoli, and cucumber [1]. It is also an endogenous molecule in all mammalian tissues [2, 3]. Its biological functions are linked to the ability to boost nicotinamide adenine dinucleotide (NAD), a product of the salvage pathway in NAD biosynthesis in which NMN serves as a precursor [2, 3]. NAD concentration declines with age affecting mammalian longevity and age-related health conditions through its functions of energy metabolization and activations of poly ADP-ribose polymerase (PARP), Sirtuin proteins, and etc. in mammalian tissues [2, 4].Many preclinical studies on NMN supplementation have been reported [2–4]. NMN treatment of Werner syndrome (WS) worms and flies with 1mM dosing elevated NAD concentrations 2.2 times higher than control and extended lifespan to 19.8 days vs. 13.9 days in control [5]. NMN intervention to healthy wild-type 3-4-month C57BL/6N mice steadily increased liver NAD concentrations over 30 min after a single oral 300 mg/kg dose, and effectively mitigated age-associated physical decline and was well tolerated after a 12-month oral treatment of 100 mg/kg/day or 300 mg/kg/day [1]. Clinical benefits of NMN supplementation in mouse models have shown doubled running endurance on aging mice [6], restored cognition in Alzheimer’s disease rat model [7], and reversed vascular dysfunction in old mice [8]. However, human clinical trials with NMN are limited [9–17]. The first human clinical trial confirmed that NMN supplementation was safe up to 500 mg/day and plasma concentrations of NAD metabolites were significantly increased, but the changes of plasma NAD concentration were not mentioned, and the trial was an open-label single oral dosing with only 10 healthy male participants [9]. The first randomized controlled trial (RCT) of NMN supplementation revealed the increases of skeletal muscle insulin sensitivity and signaling, and significant elevation of NAD concentration in peripheral blood mononuclear cell (PBMC), but found no significant change in muscle NAD concentration, and the trial used only a fixed 250 mg/day oral dose with prediabetic and obese female participants [10]. Another RCT found that the NMN supplementation was safe, but the increase of blood NAD concentration was not statistically significant with 300 mg/day oral dose on 62 middle-aged healthy men and women for 60 days [11]. A similar RCT reported that oral 300 mg/day NMN supplement was safe and significantly improved several blood biomarkers, such as HbA1c and HDL-C, but has significantly reduced blood NAD level for the 17 postmenopausal female participants after an 8-week trial [12]. A 12-week RCT with a fixed 250 mg/day oral NMN dose on 42 healthy older men showed that blood NAD concentration was significantly elevated and NMN was well tolerated, but NMN supplementation produced mixed results on skeletal muscle strength tests [13]. A separate RCT disclosed that, after intervention also with a fixed 250 mg/day NMN oral dose for 12 weeks on 30 healthy males and females, blood NAD concentration increased significantly starting at week 4 until the end of treatment at week 12 and returned to original level 4 weeks after NMN treatment, and the NMN supplementation was safe and well tolerated [14]. An RCT with 1000 and 2000 mg/day oral doses of MIB-626, a unique microcrystalline NMN formulation, on 32 overweight or obese older adults showed that blood NAD concentration was dose-dependently increased and NMN treatment was also safe and well tolerated, but the trial found that lower doses failed to significantly elevate blood NAD concentrations [15]. A 6-week RCT with healthy amateur athletes with 300, 600, and 1200 mg/day NMN oral regimens concluded that exercise plus NMN supplementation was significantly and dose-dependently increased aerobic capacity but found no impact on physical strength when compared to exercise alone [16]. Another RCT on the effects of the time-dependent intake (morning or afternoon) of NMN on sleep quality, fatigue, and physical performance in older adults was conducted with 250 mg/day NMN oral treatment for 12 weeks [17]. The trial found that only drowsiness and lower limb function in the afternoon NMN-treated group were significantly improved among the many trial end points measured. In summary, NMN supplementation was found safe and well tolerated in all the above disclosed human clinical trials [9–17]. However, only mixed results were reported on the effects of NMN to human NAD elevation [9–15] and age-related physical decline and health conditions [9–13, 16, 17]. Most of these studies used either 250 or 300 mg/day fixed dosage [10–14, 17] or only recruited either male [9, 13] or female participants [10, 12] or participants with certain health conditions such as obese and overweight [10, 15]. Further clinical studies are needed to evaluate the effects of NMN supplementation on healthy middle-aged adults of both males and females with dose-dependent oral dosing regimens in the 300-900 mg/day range on the effects of NAD concentration, safety and tolerability, and age-related physical decline and health conditions.

Product Name:	β-Nicotinamide Mononucleotide
Synonyms:	BETA-NMN;BETA-NICOTINAMIDE MONONUCLEOTIDE;BETA-NICOTINAMIDE RIBOSE MONOPHOSPHATE;3-(aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium;B-NICOTINAMIDE MONONUCLEOTIDE;NMN;NICOTINAMIDE-1-IUM-1-BETA-D-RIBOFURANOSIDE 5'-PHOSPHATE;NICOTINAMIDE RIBOTIDE
CAS:	1094-61-7
MF:	C11H15N2O8P
MW:	334.22
EINECS:	214-136-5
Product Categories:	nicotinamide mononucleotide;Pharmaceuticals;Amines;Aromatics;Bases & Related Reagents;API;Intermediates & Fine Chemicals;Nicotine Derivatives;Nucleotides;BETA-NICOTINAMI
Mol File:	1094-61-7.mol